Key Takeaways
- Agentic drug discovery is defined by autonomy across the loop: the system does not just predict, it designs, evaluates, decides, and iterates toward a goal.
- Solutions automate different parts of the loop: generative design, physical experimentation, or scientific reasoning. No single system does all three equally well.
- Physical self-driving labs are the most ambitious but also the broadest and least accessible, while focused design engines deliver value faster for a specific modality.
- Converge Bio leads the list as the strongest agentic solution for biologics, running an autonomous design-predict-optimize loop that produces antibody candidates teams can take straight into the lab, with full ownership of what it generates.
Drug discovery is a loop: design a candidate, make it, test it, learn from the result, and design again. For decades that loop moved at the speed of human hands and wet-lab calendars. Agentic AI is changing that by letting systems run parts of the loop on their own, generating hypotheses, proposing molecules, scoring them, and deciding what to try next.
The word agentic matters here. A predictive model answers one question. An agentic system pursues a goal across many steps, using tools, evaluating its own output, and iterating toward a better result. In drug discovery, that can mean an AI that designs an antibody, predicts its binding and developability, redesigns the weak candidates, and repeats, or a robotic lab that plans and runs its own experiments. Different solutions automate different parts of the loop, and the right one depends on which part of discovery is slowing your team down.
What Makes Drug Discovery “Agentic”?
Not every AI tool marketed as agentic actually is. A genuinely agentic system shows four traits, and the strongest drug discovery solutions combine several of them:
- Autonomy: it pursues a goal across multiple steps rather than answering a single query.
- Tool use: it calls models, simulations, or lab instruments to act on the world, not just describe it.
- Closed-loop iteration: it evaluates its own results and feeds them back into the next round of design or experiment.
- Reasoning: it decides what to try next based on evidence, prioritizing the most promising paths.
Mapped onto the design-make-test-learn loop, this produces three broad families. Generative design engines autonomously create and refine candidates in silico. Self-driving labs run the physical make-and-test steps with robotics. Scientific reasoning agents automate the intellectual work of hypothesis generation and analysis. The most useful solution is the one that closes the part of the loop where your program loses the most time.
The 5 Best Agentic AI Drug Discovery Solutions in 2026
1. Converge Bio: Agentic Generative Design for Biologics
Converge Bio is the Generative AI Lab for the life sciences, built on a library of biological foundation models that read and write the languages of biology. Rather than automating a physical lab, Converge automates the design core of the discovery loop, autonomously generating candidates, predicting their properties, and refining them before any wet-lab work begins.
Also Read: How the Right Accommodation Can Shape Your Travel Experience
Key capabilities
- Generative antibody design: de novo design, affinity maturation, and humanization across IgG, VHH, scFv, and bispecific formats.
- Design-predict-optimize loop: generative modeling paired with binding and developability prediction to refine candidates automatically.
- Target and biomarker discovery: ConvergeCELL simulates cellular responses to surface disease-driving targets.
- Expression optimization: ConvergeGEO tunes codons, UTRs, and promoters to improve protein yield for manufacturing.
- Zero-shot generalization: models that transfer across targets rather than needing a fresh dataset each time.
- Full ownership and privacy: customers own every molecule generated with no royalties, on private, fully managed infrastructure.
Best for
Biotech and pharma teams designing antibodies and other therapeutic proteins who want autonomous candidate generation, real developability signals, and full ownership of the results. Converge stands out for turning agentic design into practical biologics leads, backed by published case work and recent recognition of its antibody results in the industry press.
2. Lila Sciences
Lila Sciences is building autonomous AI Science Factories that aim to run the entire scientific method with limited human intervention. Its systems generate hypotheses, design experiments, execute them with robotics, and learn from the results in a continuous loop across life sciences, chemistry, and materials.
Key capabilities
- Closed-loop autonomy spanning hypothesis, experiment, execution, and learning.
- Integrated robotics that run physical experiments without manual handoffs.
- Self-generated experimental data that continuously improves its models.
- A platform model offered to partners across multiple scientific domains.
3. Recursion
Recursion treats drug discovery as a data problem, running one of the most industrialized automated-experimentation operations in the field. It generates vast libraries of cellular images and perturbation data, then trains foundation models to map relationships between genes, compounds, and disease before a target is chosen.
Key capabilities
- Massive proprietary datasets from automated cellular imaging.
- Foundation models that map biology and chemistry at scale.
- Recursion OS connecting wet-lab automation with computational modeling.
- Broad disease-biology exploration and large pharma partnerships.
4. Future House
Future House focuses on the intellectual side of discovery, building AI agents that reason like scientists. Its multi-agent systems autonomously search the literature, generate hypotheses, plan analyses, and connect scientific tools, aiming to automate the research thinking that precedes and surrounds experiments.
Key capabilities
- Multi-agent systems that generate and test scientific hypotheses.
- Automated literature search and evidence synthesis at scale.
- Experiment planning and analysis across research workflows.
- A stated goal of building a general AI scientist.
5. Isomorphic Labs
Isomorphic Labs is an AI-first drug design company built on the protein-structure modeling lineage that reshaped computational biology. It uses foundation models to predict how molecules and targets interact and to design new candidates, with a focus on small molecules and major pharmaceutical partnerships.
Key capabilities
- Advanced structure and interaction prediction for molecular design.
- AI-first generative design of new drug candidates.
- Partnerships with large pharmaceutical companies.
- A pipeline preparing AI-designed candidates for clinical testing.
Matching an Agentic Solution to Your Discovery Bottleneck
The right agentic solution is the one that closes the part of the loop where your program loses the most time. A quick way to decide:
- If antibody or protein design is the bottleneck: a generative design engine that autonomously proposes and refines candidates is the highest-leverage choice, which is where Converge Bio is strongest.
- If lab throughput is the bottleneck: a self-driving lab that runs physical experiments continuously, such as Lila Sciences, addresses the make-and-test constraint directly.
- If biological mapping is the bottleneck: an industrialized data-generation platform like Recursion helps uncover targets before design begins.
- If research reasoning is the bottleneck: AI scientist agents such as Future House accelerate hypothesis generation and literature synthesis.
- If small-molecule structure is the bottleneck: an AI-first design engine like Isomorphic Labs focuses on interaction prediction and candidate design.
Most teams will combine more than one, pairing a design engine with a source of experimental or biological data so the agentic loop keeps improving.
Frequently Asked Questions
What is agentic AI in drug discovery?
Agentic AI in drug discovery describes systems that pursue a research goal across many steps rather than answering a single question. They design candidates, use tools or lab instruments, evaluate their own results, and iterate toward a better outcome. Platforms like Converge Bio apply this to biologics, autonomously generating, scoring, and refining antibody candidates through a closed design loop before any experiment runs.
How is agentic AI different from regular AI drug discovery tools?
Regular AI tools predict a property or rank a dataset, while agentic AI acts across the discovery loop. An agentic system does not stop at a prediction; it decides what to design next, refines weak candidates, and learns from each round. That autonomy is why agentic solutions can compress work that once took many manual cycles, especially in large search spaces like antibody design.
Is Converge Bio a good fit for antibody discovery?
Converge Bio is a strong fit for antibody discovery because its ConvergeAB engine runs an agentic design loop built for that exact problem. It performs de novo design, affinity maturation, and humanization across IgG, VHH, scFv, and bispecific formats, pairing generative design with developability prediction. Teams receive experiment-ready candidates they fully own, which shortens the path from target to lead.
Can agentic AI run drug discovery without scientists?
No. Agentic AI automates parts of the discovery loop, but scientists still set goals, interpret results, and make strategic decisions. Self-driving labs run experiments and design engines generate candidates, yet human judgment guides which directions matter and validates what the systems produce. The goal is to remove repetitive cycles and expand what a team can explore, not to replace scientific oversight.
What are the main types of agentic drug discovery solutions?
Agentic drug discovery solutions fall into three families. Generative design engines such as Converge Bio autonomously create and refine candidates in silico. Self-driving labs like Lila Sciences run physical experiments with robotics. Scientific reasoning agents such as Future House automate hypothesis generation and analysis. Many programs combine these families so the design, experiment, and learning stages of the loop reinforce one another.
Who owns the molecules an agentic AI platform generates?
Ownership varies by platform and is worth confirming before committing. Some providers retain rights or royalties on what their systems produce. Converge Bio is notable for giving customers full ownership of every molecule generated, with no royalties, on private and fully managed infrastructure. For teams building a proprietary pipeline, that ownership model can be as important as the underlying AI performance.